Frontlight ResearchEarly access
CompletedPhase 2
BCAAs in Concussion 2.0
Key facts
- Who runs it
- Akiva Cohen
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 17 people enrolled
- Started
- 1 Apr 2025
- Ended
- 1 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BCAA
- Placebo
- Record updated
- 3 September 2026
Who can take part
- Age
- 11 years to 23 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Males and females,11 - 23 years of age
- Weigh at least 40kg
- Meeting concussion criteria for the American Congress of Rehabilitative Medicine
- Present within 4 days of injury
- Post-menarchal females must have a negative urine pregnancy test and must use an acceptable method of contraception
- Informed consent by the participant, or for participants <18 years old both informed consent by a parent/guardian and child assent
Who cannot take part
- Prior concussion or TBI within 90 days
- Any investigational drug use within 30 days prior to enrollment
- Known history of maple syrup urine disease or known family history of maple syrup urine disease
- Hypersensitivity to any ingredient in the active or placebo products
- Evidence of moderate or severe Traumatic Brain Injury (TBI), including Glasgow Coma Scale (GCS) <13, TBI requiring hospital admission, or TBI requiring neurosurgical intervention
- Participants who are pregnant, planning on becoming pregnant during the study duration, or breastfeeding
- Non-English speaking participants or parent/guardian
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.
The 2 groups in the trial
- Drug: Branched Chain Amino AcidsTreatment being tested
The three BCAAs will be combined together and dissolved into a flavored solution.
Treatment: BCAA
- PlaceboPlacebo, for comparison
The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- HIT HEADS 2.0: Head Injury Treatment: A Randomized, Placebo-controlled, Double-blinded, Therapeutic Clinical Trial of Branched Chain Amino Acids (BCAAs) in the Treatment of Concussion
- Record updated
- 3 September 2026